"
Team:NRP-UEA-Norwich/Judging Criteria
From 2014.igem.org
(Difference between revisions)
Nicolapatron (Talk | contribs) |
|||
| (8 intermediate revisions not shown) | |||
| Line 17: | Line 17: | ||
<link href="//maxcdn.bootstrapcdn.com/font-awesome/4.1.0/css/font-awesome.min.css" rel="stylesheet"> | <link href="//maxcdn.bootstrapcdn.com/font-awesome/4.1.0/css/font-awesome.min.css" rel="stylesheet"> | ||
<style type="text/css"> | <style type="text/css"> | ||
| - | body{font-family:'Open Sans',sans-serif;font-size:13px}header{box-shadow:0 6px 6px rgba(0,0,0,.3)}header .container{height:80px}header .logo{padding:10px 0 10px 80px}header .igem{position:absolute;top:20px;right:-50px;z-index:100}header .igem img{width:40px;height:40px}header ul{float:right;list-style:none}header ul li{display:inline-block;white-space:nowrap}header ul li a{display:block;padding:0 15px;height:80px;line-height:80px;color:#000;text-decoration:none!important;transition:background-color .2s linear}header ul li a:active,header ul li a:hover,header ul li a:visited{background-color:#ecffeb;text-decoration:none!important;color:#000}header ul.dropdown-menu li{display:block}header ul.dropdown-menu li a{height:auto;padding:6px 20px;text-decoration:none}section{padding:50px 0}section h1{font-weight:300;font-size:48px;padding:0 0 50px}.dropdown-menu{margin:0}ul.menu li.dropdown:hover>ul.dropdown-menu{display:block}.bx-wrapper img{display:block;max-width:100%;min-width:970px;margin:0 auto}.welcome{padding:80px 0;background:url(https://static.igem.org/mediawiki/2014/0/06/Uea_header-bg.png)}.about{background:url(https://static.igem.org/mediawiki/2014/d/d7/Uea_body-bg.png)}.about h2{font-size:18px;font-weight:700}.about p.project{font-size:14px;padding:10px}.about p.project:last-of-type{padding-bottom:40px}.about .row:first-of-type{margin-bottom:40px}.about .col-md-4 i{transition:color .2s linear}.about .col-md-4:hover i{color:#2ECC71}.team{background:url(https://static.igem.org/mediawiki/2014/d/d7/Uea_body-bg.png);transition:all .3s linear;padding:0 0 40px}.team .img-responsive{border-radius:20em;-webkit-border-radius:20em;-moz-border-radius:20em;-webkit-filter:grayscale(100%);-moz-filter:grayscale(100%);-ms-filter:grayscale(100%);filter:grayscale(100%);filter:gray;transition:all .3s linear;max-width:200px;margin:0 auto}.team .col-md-4:hover .img-responsive{-webkit-filter:none;-moz-filter:none;-ms-filter:none;filter:none}.team .row:first-of-type{margin-bottom:40px}.team h2{font-size:18px;font-weight:700;color:#019875}.team h3{font-size:13px;font-weight:700;color:#019875}.team .col-md-3{padding:0 30px}.team .meetourteam{margin-bottom:60px}.social{background:url(https://static.igem.org/mediawiki/2014/d/d7/Uea_body-bg.png)}.sponsors .col-md-2{display:table;height:90px}.sponsors .middle{display:table-cell;vertical-align:middle}.sponsors .row:first-of-type{margin-bottom:40px}.general{padding-top:0;background:url(https://static.igem.org/mediawiki/2014/d/d7/Uea_body-bg.png)}.title{background:url(https://static.igem.org/mediawiki/2014/0/06/Uea_header-bg.png)}.title h1,.title h2{text-align:center}.title h1{margin-top:0;padding:40px 0;margin-bottom:40px}.title h2{font-size:18px;color:#999;margin:0 0 50px;padding-bottom:40px}.general p{margin:0 0 40px}.fa-8x{font-size:8em;color:#019875}.row .boxed-headline{width:100%;height:200px;background-color:#90C695}.container .overview{padding-bottom:40px}footer{color:#444;background-color:#F2F1EF;padding:50px 0}footer ul.sponsors{float:left;width:100%;padding:0;margin:20px 0 0;list-style-type:none}footer ul.sponsors li{display:inline;padding:0 20px}footer ul.sponsors li img{width:90px}#top-section{border:0;height:14px;z-index:100;top:0;position:fixed;width:975px;left:50%;margin-left:-487px;background-color:transparent}#content,#globalWrapper{width:100%;height:100%;border:0;background-color:transparent;margin:0;padding:0;font-size:100%}#catlinks,#contentSub,#footer-box,#p-logo,#search-controls,#sitesub,.firstHeading,.printfooter,.visualClear{display:none}h1,h2,h3,h4,h5,h6{border-bottom:none}#bodyContent h1,#bodyContent h2{margin-bottom:40px} | + | body{font-family:'Open Sans',sans-serif;font-size:13px}header{box-shadow:0 6px 6px rgba(0,0,0,.3)}header .container{height:80px}header .logo{padding:10px 0 10px 80px}header .igem{position:absolute;top:20px;right:-50px;z-index:100}header .igem img{width:40px;height:40px}header ul{float:right;list-style:none}header ul li{display:inline-block;white-space:nowrap}header ul li a{display:block;padding:0 15px;height:80px;line-height:80px;color:#000;text-decoration:none!important;transition:background-color .2s linear}header ul li a:active,header ul li a:hover,header ul li a:visited{background-color:#ecffeb;text-decoration:none!important;color:#000}header ul.dropdown-menu li{display:block}header ul.dropdown-menu li a{height:auto;padding:6px 20px;text-decoration:none}section{padding:50px 0}section h1{font-weight:300;font-size:48px;padding:0 0 50px}.dropdown-menu{margin:0}ul.menu li.dropdown:hover>ul.dropdown-menu{display:block}.bx-wrapper img{display:block;max-width:100%;min-width:970px;margin:0 auto}.welcome{padding:80px 0;background:url(https://static.igem.org/mediawiki/2014/0/06/Uea_header-bg.png)}.about{background:url(https://static.igem.org/mediawiki/2014/d/d7/Uea_body-bg.png)}.about h2{font-size:18px;font-weight:700}.about p.project{font-size:14px;padding:10px}.about p.project:last-of-type{padding-bottom:40px}.about .row:first-of-type{margin-bottom:40px}.about .col-md-4 i{transition:color .2s linear}.about .col-md-4:hover i{color:#2ECC71}.team{background:url(https://static.igem.org/mediawiki/2014/d/d7/Uea_body-bg.png);transition:all .3s linear;padding:0 0 40px}.team .img-responsive{border-radius:20em;-webkit-border-radius:20em;-moz-border-radius:20em;-webkit-filter:grayscale(100%);-moz-filter:grayscale(100%);-ms-filter:grayscale(100%);filter:grayscale(100%);filter:gray;transition:all .3s linear;max-width:200px;margin:0 auto}.team .col-md-4:hover .img-responsive{-webkit-filter:none;-moz-filter:none;-ms-filter:none;filter:none}.team .row:first-of-type{margin-bottom:40px}.team h2{font-size:18px;font-weight:700;color:#019875}.team h3{font-size:13px;font-weight:700;color:#019875}.team .col-md-3{padding:0 30px}.team .meetourteam{margin-bottom:60px}.social{background:url(https://static.igem.org/mediawiki/2014/d/d7/Uea_body-bg.png)}.sponsors .col-md-2{display:table;height:90px}.sponsors .middle{display:table-cell;vertical-align:middle}.sponsors .row:first-of-type{margin-bottom:40px}.general{padding-top:0;background:url(https://static.igem.org/mediawiki/2014/d/d7/Uea_body-bg.png)}.title{background:url(https://static.igem.org/mediawiki/2014/0/06/Uea_header-bg.png)}.title h1,.title h2{text-align:center}.title h1{margin-top:0;padding:40px 0;margin-bottom:40px}.title h2{font-size:18px;color:#999;margin:0 0 50px;padding-bottom:40px}.general p{margin:0 0 40px}.fa-8x{font-size:8em;color:#019875}.row .boxed-headline{width:100%;height:200px;background-color:#90C695}.container .overview{padding-bottom:40px}footer{color:#444;background-color:#F2F1EF;padding:50px 0}footer ul.sponsors{float:left;width:100%;padding:0;margin:20px 0 0;list-style-type:none}footer ul.sponsors li{display:inline;padding:0 20px}footer ul.sponsors li img{width:90px}#top-section{border:0;height:14px;z-index:100;top:0;position:fixed;width:975px;left:50%;margin-left:-487px;background-color:transparent}#content,#globalWrapper{width:100%;height:100%;border:0;background-color:transparent;margin:0;padding:0;font-size:100%}#catlinks,#contentSub,#footer-box,#p-logo,#search-controls,#sitesub,.firstHeading,.printfooter,.visualClear{display:none}h1,h2,h3,h4,h5,h6{border-bottom:none}#bodyContent h1,#bodyContent h2{margin-bottom:40px}.col-md-1,.col-md-10,.col-md-11,.col-md-12,.col-md-2,.col-md-3,.col-md-4,.col-md-5,.col-md-6,.col-md-7,.col-md-8,.col-md-9{float:left}.col-md-12{width:100%}.col-md-11{width:91.66666667%}.col-md-10{width:83.33333333%}.col-md-9{width:75%}.col-md-8{width:66.66666667%}.col-md-7{width:58.33333333%}.col-md-6{width:50%}.col-md-5{width:41.66666667%}.col-md-4{width:33.33333333%}.col-md-3{width:25%}.col-md-2{width:16.66666667%}.col-md-1{width:8.33333333%}.container{min-width:970px}ul.bxslider{margin:0 !important} |
</style> | </style> | ||
</head> | </head> | ||
| Line 35: | Line 35: | ||
<img src="https://static.igem.org/mediawiki/2014/e/e0/Uea_logo.png" class="logo"/> | <img src="https://static.igem.org/mediawiki/2014/e/e0/Uea_logo.png" class="logo"/> | ||
<div class="igem"> | <div class="igem"> | ||
| - | <a href="https://2014.igem.org/Main_Page"/><img src="https://static.igem.org/mediawiki/2014/a/a3/Uea_igem-logo.png"/></a> | + | <a href="https://2014.igem.org/Main_Page"/ target="_blank"><img src="https://static.igem.org/mediawiki/2014/a/a3/Uea_igem-logo.png"/></a> |
</div> | </div> | ||
</div> | </div> | ||
| Line 59: | Line 59: | ||
<li><a href="https://2014.igem.org/Team:NRP-UEA-Norwich/Project_Mo-Flipper">Golden Gate Modular Flipper</a></li> | <li><a href="https://2014.igem.org/Team:NRP-UEA-Norwich/Project_Mo-Flipper">Golden Gate Modular Flipper</a></li> | ||
<li><a href="https://2014.igem.org/Team:NRP-UEA-Norwich/HP_Collaborations">Collaborations</a></li> | <li><a href="https://2014.igem.org/Team:NRP-UEA-Norwich/HP_Collaborations">Collaborations</a></li> | ||
| + | <li><a href="https://2014.igem.org/Team:NRP-UEA-Norwich/Judging_Criteria">Judging Criteria</a></li> | ||
</ul> | </ul> | ||
</li> | </li> | ||
| Line 74: | Line 75: | ||
<li><a href="https://2014.igem.org/Team:NRP-UEA-Norwich/HP_CUT">The CUT event</a></li> | <li><a href="https://2014.igem.org/Team:NRP-UEA-Norwich/HP_CUT">The CUT event</a></li> | ||
<li><a href="https://2014.igem.org/Team:NRP-UEA-Norwich/HP_School-Events">The Hewett School</a></li> | <li><a href="https://2014.igem.org/Team:NRP-UEA-Norwich/HP_School-Events">The Hewett School</a></li> | ||
| - | <li><a href="https://2014.igem.org/Team:NRP-UEA-Norwich/HP_Science-Cafe">Science | + | <li><a href="https://2014.igem.org/Team:NRP-UEA-Norwich/HP_Science-Cafe">Science Café</a></li> |
<li><a href="https://2014.igem.org/Team:NRP-UEA-Norwich/HP_Ethics">Ethics of Public Consultation</a></li> | <li><a href="https://2014.igem.org/Team:NRP-UEA-Norwich/HP_Ethics">Ethics of Public Consultation</a></li> | ||
</ul> | </ul> | ||
| Line 81: | Line 82: | ||
<a data-toggle="dropdown" class="dropdown-toggle" href="#">Safety <span class="caret"></span></a> | <a data-toggle="dropdown" class="dropdown-toggle" href="#">Safety <span class="caret"></span></a> | ||
<ul class="dropdown-menu"> | <ul class="dropdown-menu"> | ||
| - | <li><a href="https://2014.igem.org/Team:NRP-UEA-Norwich/ | + | <li><a href="https://2014.igem.org/Team:NRP-UEA-Norwich/Safety">Safety Overview</a></li> |
<li><a href="https://2014.igem.org/Team:NRP-UEA-Norwich/Safety_RA">Risk Assessments</a></li> | <li><a href="https://2014.igem.org/Team:NRP-UEA-Norwich/Safety_RA">Risk Assessments</a></li> | ||
<li><a href="https://2014.igem.org/Team:NRP-UEA-Norwich/Safety_UEA">UEA Safety</a></li> | <li><a href="https://2014.igem.org/Team:NRP-UEA-Norwich/Safety_UEA">UEA Safety</a></li> | ||
| Line 109: | Line 110: | ||
<h1 align="center"><font color="996633" size="20"><b>Bronze</b></font></h1> | <h1 align="center"><font color="996633" size="20"><b>Bronze</b></font></h1> | ||
| - | <table width="70%" border="1" summary="Bronze" align="center" cellspacing="10" cellpadding=" | + | <table width="70%" border="1" summary="Bronze" align="center" cellspacing="10" cellpadding="10"> |
| Line 151: | Line 152: | ||
and submit this part to the iGEM Registry.</td> | and submit this part to the iGEM Registry.</td> | ||
<td> | <td> | ||
| - | <li>The apoptosis regulator <a href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K1467203">Bax</a> .</li> | + | <li>The apoptosis regulator <a href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K1467203" target="_blank">Bax</a> .</li> |
| - | <li>The plant specific promoter <a href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K1467102">BS3</a> which is induced by the TALE AvrBS3.</li> | + | <li>The plant specific promoter <a href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K1467102" target="_blank">BS3</a> which is induced by the TALE AvrBS3.</li> |
| - | <li>The methyl-jasmonate induced plant specific promoter <a href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K1467103">PDF 1.2</a></li> | + | <li>The methyl-jasmonate induced plant specific promoter <a href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K1467103" target="_blank">PDF 1.2</a></li> |
| - | <li>The <a href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K1467205">AvrBS3</a> TAL Effector which induces the BS3 promoter.</li> | + | <li>The <a href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K1467205" target="_blank">AvrBS3</a> TAL Effector which induces the BS3 promoter.</li> |
</td> | </td> | ||
</tr> | </tr> | ||
| Line 177: | Line 178: | ||
<tr> | <tr> | ||
<td>Experimentally validate that at least one new BioBrick Part or Device of your own design and construction works as expected.</td> | <td>Experimentally validate that at least one new BioBrick Part or Device of your own design and construction works as expected.</td> | ||
| - | <td><li>The apoptosis regulator <a href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K1467203">Bax</a> works as expected and rapidly induced cell death in leaves.</li> | + | <td><li>The apoptosis regulator <a href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K1467203" target="_blank">Bax</a> works as expected and rapidly induced cell death in leaves.</li> |
| - | <li>The plant specific promoter <a href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K1467102">BS3</a> was able to drive expression of coding sequences in plants only in the presence of the TALE, AvrBS3.</li><li>The <a href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K1467205">AvrBS3</a> TAL Effector was able to induce expression from the BS3 promoter.</li> | + | <li>The plant specific promoter <a href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K1467102" target="_blank">BS3</a> was able to drive expression of coding sequences in plants only in the presence of the TALE, AvrBS3.</li><li>The <a href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K1467205" target="_blank">AvrBS3</a> TAL Effector was able to induce expression from the BS3 promoter.</li> |
| - | <li>The methyl-jasmonate induced plant specific promoter <a href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K1467103">PDF 1.2</a> was able to drive expression of coding regions in plants. Expression was up-regulated by methyl-jasmonate but there was some background expression, probably caused by our delivery chassis (Agrobacterium tumefaciens)</li> | + | <li>The methyl-jasmonate induced plant specific promoter <a href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K1467103" target="_blank">PDF 1.2</a> was able to drive expression of coding regions in plants. Expression was up-regulated by methyl-jasmonate but there was some background expression, probably caused by our delivery chassis (Agrobacterium tumefaciens)</li> |
</td> | </td> | ||
</tr> | </tr> | ||
| Line 185: | Line 186: | ||
<tr> | <tr> | ||
<td>Document the characterisation of this part in the “Main Page” section of that Part’s/Device’s Registry entry.</td> | <td>Document the characterisation of this part in the “Main Page” section of that Part’s/Device’s Registry entry.</td> | ||
| - | <td>We have documented the use of our parts in the registry: <li>The apoptosis regulator <a href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K1467203">Bax</a> </li> | + | <td>We have documented the use of our parts in the registry: <li>The apoptosis regulator <a href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K1467203" target="_blank">Bax</a> </li> |
| - | <li>The plant specific promoter <a href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K1467102">BS3</a> </li><li>The <a href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K1467205">AvrBS3</a> TAL Effector </li> | + | <li>The plant specific promoter <a href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K1467102" target="_blank">BS3</a> </li><li>The <a href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K1467205" target="_blank">AvrBS3</a> TAL Effector </li> |
| - | <li>The methyl-jasmonate induced plant specific promoter <a href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K1467103">PDF 1.2</a> </li></td> | + | <li>The methyl-jasmonate induced plant specific promoter <a href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K1467103" target="_blank">PDF 1.2</a> </li></td> |
</tr> | </tr> | ||
<tr> | <tr> | ||
<td>Submit this new part to the iGEM Parts Registry.</td> | <td>Submit this new part to the iGEM Parts Registry.</td> | ||
| - | <td>All the parts above, plus a few more, were submitted to the registry. <a href="http://parts.igem.org/cgi/partsdb/pgroup.cgi?pgroup=iGEM2014&group=NRP-UEA-Norwich">See our team parts page</a></td> | + | <td>All the parts above, plus a few more, were submitted to the registry. <a href="http://parts.igem.org/cgi/partsdb/pgroup.cgi?pgroup=iGEM2014&group=NRP-UEA-Norwich" target="_blank">See our team parts page</a></td> |
</tr> | </tr> | ||
| Line 224: | Line 225: | ||
<td>Improve the function OR characterization of an existing BioBrick Part or Device (created by another team or your own institution | <td>Improve the function OR characterization of an existing BioBrick Part or Device (created by another team or your own institution | ||
in a previous year), enter this information in the Registry.</td> | in a previous year), enter this information in the Registry.</td> | ||
| - | <td>Our team has improved <a href="http://parts.igem.org/Part:BBa_J04450:Experience">BBa_J04450</a> by adding flanking sequences to make a series of four "GoldenGate Flipper modules" (Documented as <a href="http://parts.igem.org/Part:BBa_K1467100">BBa_K1467100</a>, <a href="http://parts.igem.org/Part:BBa_K1467200">BBa_K1467200</a>, <a href="http://parts.igem.org/Part:BBa_K1467300">BBa_K1467300</a> and <a href="http://parts.igem.org/Part:BBa_K1467400">BBa_K1467400</a>) that can be used to convert four types of standard part defined in the GoldenGate MoClo Assembly Standard into standard BioBricks. This was done by inserting an inverted pair of BsaI recognition sequences either side of the original RFP reporter part. The flipper reaction is a one-pot, one-step, digestion-ligation GoldenGate cloning reaction. When cloning is successful the colonies become white as the RFP sequence is replaced by the new part. After the reaction is complete, no part of the BsaI recognition sequence will remain between the BioBrick suffix and the part. | + | <td>Our team has improved <a href="http://parts.igem.org/Part:BBa_J04450:Experience" target="_blank">BBa_J04450</a> by adding flanking sequences to make a series of four "GoldenGate Flipper modules" (Documented as <a href="http://parts.igem.org/Part:BBa_K1467100" target="_blank">BBa_K1467100</a>, <a href="http://parts.igem.org/Part:BBa_K1467200" target="_blank">BBa_K1467200</a>, <a href="http://parts.igem.org/Part:BBa_K1467300" target="_blank">BBa_K1467300</a> and <a href="http://parts.igem.org/Part:BBa_K1467400" target="_blank">BBa_K1467400</a>) that can be used to convert four types of standard part defined in the GoldenGate MoClo Assembly Standard into standard BioBricks. This was done by inserting an inverted pair of BsaI recognition sequences either side of the original RFP reporter part. The flipper reaction is a one-pot, one-step, digestion-ligation GoldenGate cloning reaction. When cloning is successful the colonies become white as the RFP sequence is replaced by the new part. After the reaction is complete, no part of the BsaI recognition sequence will remain between the BioBrick suffix and the part. |
</td> | </td> | ||
<tr> | <tr> | ||
| Line 231: | Line 232: | ||
<td>Help any registered iGEM team from another school or institution by, for example, characterizing a part, debugging a construct, | <td>Help any registered iGEM team from another school or institution by, for example, characterizing a part, debugging a construct, | ||
or modeling or simulating their system.</td> | or modeling or simulating their system.</td> | ||
| - | <td>We collaborated with two other teams (<a href="https://2014.igem.org/Team:Valencia_UPV">Valencia UPV</a> and <a href="https://2014.igem.org/Team:Cambridge-JIC">Cambridge-JIC</a> who had chosen to use a plant chassis and were interested in GoldenGate cloning to develop a new RFC for plants!! We also sent Team <a href="https://2014.igem.org/Team:Valencia_UPV">Valencia UPV</a> chromoproteins (AmilCP and AmilGFP) and our Flipper parts (see above) for converting any of their GoldenGate parts to BioBricks for submission to the registry. </td> | + | <td>We collaborated with two other teams (<a href="https://2014.igem.org/Team:Valencia_UPV" target="_blank">Valencia UPV</a> and <a href="https://2014.igem.org/Team:Cambridge-JIC" target="_blank">Cambridge-JIC</a> who had chosen to use a plant chassis and were interested in GoldenGate cloning to develop a new RFC for plants!! We also sent Team <a href="https://2014.igem.org/Team:Valencia_UPV" target="_blank">Valencia UPV</a> chromoproteins (AmilCP and AmilGFP) and our Flipper parts (see above) for converting any of their GoldenGate parts to BioBricks for submission to the registry. </td> |
</tr> | </tr> | ||
Latest revision as of 15:20, 17 October 2014
Judging Criteria
& how NRP-UEA iGEM have fulfilled them!
Bronze
| Requirement | Notes |
|---|---|
| Team Registration. | Team is registered. |
| Complete Judging Form. | Judging Form completed. |
| Team Wiki. | Wiki is live. |
| Present a poster and talk at the iGEM Jamboree. | Poster and Presentation in final stages. |
| The description of each project must clearly attribute work done by the students and distinguish it from work done by others, including host labs, advisors, instructors, sponsors, professional website designers, artists, and commercial services. | Contributions from those outside of the team are stated on our Attributions page |
| Document at least one new standard BioBrick Part or Device used in your project/central to your project and submit this part to the iGEM Registry. |
|
Silver
| Requirement | Notes |
|---|---|
| Experimentally validate that at least one new BioBrick Part or Device of your own design and construction works as expected. | |
| Document the characterisation of this part in the “Main Page” section of that Part’s/Device’s Registry entry. | We have documented the use of our parts in the registry: |
| Submit this new part to the iGEM Parts Registry. | All the parts above, plus a few more, were submitted to the registry. See our team parts page |
| iGEM projects involve important questions beyond the bench, for example relating to (but not limited to) ethics, sustainability, social justice, safety, security, or intellectual property rights. Articulate at least one question encountered by your team, and describe how your team considered the(se) question(s) within your project. Include attributions to all experts and stakeholders consulted. | Our project uses a plant chassis. Historically, especially in Europe, the media and general public have not accepted the genetic modification of plants. As our plants are designed as 'sentinels' (early-warning canaries!) and not as food plants, we were interested to find out how people would respond. We were also interested in whether people thought scientists have an ethical obligation to work towards food security and if they thought that biotechnology and synthetic biology should be used to meet that need. Please see the Policy and Practices page to read about this work. Contributions from others are documented on out Attributions page. |
Gold
| Requirement | Notes |
|---|---|
| Improve the function OR characterization of an existing BioBrick Part or Device (created by another team or your own institution in a previous year), enter this information in the Registry. | Our team has improved BBa_J04450 by adding flanking sequences to make a series of four "GoldenGate Flipper modules" (Documented as BBa_K1467100, BBa_K1467200, BBa_K1467300 and BBa_K1467400) that can be used to convert four types of standard part defined in the GoldenGate MoClo Assembly Standard into standard BioBricks. This was done by inserting an inverted pair of BsaI recognition sequences either side of the original RFP reporter part. The flipper reaction is a one-pot, one-step, digestion-ligation GoldenGate cloning reaction. When cloning is successful the colonies become white as the RFP sequence is replaced by the new part. After the reaction is complete, no part of the BsaI recognition sequence will remain between the BioBrick suffix and the part. |
| Help any registered iGEM team from another school or institution by, for example, characterizing a part, debugging a construct, or modeling or simulating their system. | We collaborated with two other teams (Valencia UPV and Cambridge-JIC who had chosen to use a plant chassis and were interested in GoldenGate cloning to develop a new RFC for plants!! We also sent Team Valencia UPV chromoproteins (AmilCP and AmilGFP) and our Flipper parts (see above) for converting any of their GoldenGate parts to BioBricks for submission to the registry. |
| iGEM projects involve important questions beyond the bench, for example relating to (but not limited to) ethics, sustainability, social justice, safety, security, or intellectual property rights. Describe an approach that your team used to address at least one of these questions. Evaluate your approach, including whether it allowed you to answer your question(s), how it influenced the team’s scientific project, and how it might be adapted for others to use (within and beyond iGEM). | After our initial Policy and Practices event, we once again ventured out again to facilitate a more in-depth discussion in a ‘Science Café’ style debate on the topics surrounding our project, which included: genetic modification of plants and other organisms, crop disease, food security, the ethics behind scientific discovery, and the way scientists conduct themselves. We followed up this event with the ethics committee at our university initiate a process of ethical public consultation on these issues. More information on both of these studies are given on our Policy and Practices page. Contributions are detailed on ourAttributions page. |
